Evidence map›Paper›PMID 20425268›Full record

ReviewCurrent atherosclerosis reports2010

Lp-PLA2: A new target for statin therapy.

Lynne T Braun, Michael H Davidson

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current atherosclerosis reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Cardiovascular Disease, Statins, and HIV.The Journal of infectious diseases · 2016
    Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lynne T BraunRush Heart and Vascular Institute, Rush University Medical Center, 1725 W. Harrison, Suite 1159, Chicago, IL 60612, USA. lynne_t_braun@rush.edu
Michael H Davidson

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammation plays an important role in atherogenesis and plaque vulnerability. Inflammatory-type markers have been evaluated for their association with atherosclerotic vascular disease and their ability to improve cardiovascular disease (CVD) risk stratification. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is a vascular-specific inflammatory enzyme that increases the risk of CVD events and stroke approximately twofold. A consensus panel recently recommended the measurement of Lp-PLA(2) in moderate-risk and high-risk patients for improved risk stratification and modification of low-density lipoprotein target levels. Lipid-lowering agents, particularly statins, lower Lp-PLA(2) mass and activity; therefore, Lp-PLA(2) may represent an important target of lipid-lowering therapy for reducing the inflammatory nature of atherosclerosis and plaque vulnerability. It is unknown whether lowering inflammatory markers such as Lp-PLA(2) will have a direct benefit on CVD events and mortality. A large morbidity and mortality trial was recently initiated to evaluate the long-term safety and efficacy of darapladib, an Lp-PLA(2) antagonist, in patients with high-risk coronary heart disease.

Indexed as

1-Alkyl-2-acetylglycerophosphocholine EsteraseBiomarkersCoronary DiseaseHumansHydroxymethylglutaryl-CoA Reductase InhibitorsInflammationMorbidityPrognosisRisk FactorsSurvival Rate1-Alkyl-2-acetylglycerophosphocholine EsteraseBiomarkersHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID20425268

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.